AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
3.190
+0.040 (1.27%)
Dec 15, 2025, 3:02 PM EST - Market open
AC Immune Employees
As of December 31, 2024, AC Immune had 172 total employees, including 133 full-time and 39 part-time employees. The number of employees increased by 11 or 6.83% compared to the previous year.
Employees
172
Change (1Y)
11
Growth (1Y)
6.83%
Revenue / Employee
$31,878
Profits / Employee
-$524,035
Market Cap
315.63M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 172 | 11 | 6.83% |
| Dec 31, 2023 | 161 | 5 | 3.21% |
| Dec 31, 2022 | 156 | 7 | 4.70% |
| Dec 31, 2020 | 149 | 17 | 12.88% |
| Dec 31, 2019 | 132 | 28 | 26.92% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACIU News
- 26 minutes ago - AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD - Seeking Alpha
- 4 days ago - AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - Benzinga
- 4 days ago - AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease - GlobeNewsWire
- 5 weeks ago - AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 7 weeks ago - First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine - GlobeNewsWire
- 4 months ago - AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 8 months ago - AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 9 months ago - AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - GlobeNewsWire